Adocia
About
History
Management
Board of directors
Advisory board
Products and platforms
Pipeline
Technology Platforms
Careers
The « Adocians »
HR policy
Work environment
Join us
Partnering
Investors
Media
Contact
Contact us
Map and accessibility
Investors
Regulated information
Stock information
Corporate governance
General meeting
Media
Press releases
Media
EN
FR
Number of shares and voting rights of ADOCIA as of August 31, 2018
Previous article
Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes
Next article
“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
